Retatrutide: The Triple Receptor Agonist Explained

A new class of metabolic research compound

Retatrutide (development code LY3437943) is an investigational triple receptor agonist. In a single molecule it activates three receptors that regulate metabolism and energy balance: GIP, GLP-1, and the glucagon receptor. That third target is what sets it apart from the compounds that came before it.

The three pathways

• GLP-1 (glucagon-like peptide-1): an incretin receptor tied to glucose-dependent insulin signaling and satiety pathways. This is the target of semaglutide.
• GIP (glucose-dependent insulinotropic polypeptide): a second incretin receptor. Tirzepatide adds this to GLP-1, making it a dual agonist.
• Glucagon receptor: linked in research to energy expenditure and hepatic lipid metabolism. Retatrutide adds this third arm.

Where it sits in the family

The GLP-1 research class has progressed from single-target (semaglutide) to dual (tirzepatide) to triple (retatrutide). Each receptor added broadens the set of metabolic pathways under study in a single molecule.

Research status

Retatrutide is investigational. It has moved through early- and mid-stage clinical research and into larger metabolic trials, but it is not an approved product. It is supplied here strictly as a lyophilized research compound. For laboratory research use only. Not for human consumption.